迈得医疗(688310) - 2024 Q4 - 年度业绩预告

Financial Projections - The company expects to achieve an operating revenue of approximately 273.18 million yuan in 2024, a decrease of about 207.04 million yuan, representing a year-on-year decline of approximately 43.11%[4] - The net profit attributable to the parent company is projected to be around -22.21 million yuan, a decrease of about 122.25% compared to the previous year, which reflects a reduction of approximately 122.04 million yuan[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be around -30.52 million yuan, a decrease of about 135.01% year-on-year, equating to a reduction of approximately 117.70 million yuan[4] Previous Year Financials - The total profit for the previous year was 127.43 million yuan[6] - The net profit attributable to the parent company for the previous year was 99.83 million yuan[7] - The net profit attributable to the parent company after deducting non-recurring gains and losses for the previous year was 87.18 million yuan[8] - Basic earnings per share for the previous year were 0.85 yuan[9] Revenue Decline Factors - The decrease in revenue is attributed to fluctuations in downstream market demand, reduced customer investment willingness, increased competition, and some customers being unable to ship due to factory issues[10] Expenses and Impairment - Increased R&D and management expenses are due to ongoing investments in R&D projects and the development of new business lines[10] - The company is undergoing a preliminary impairment test on goodwill related to the acquisition of Zhejiang Weigao Automation Equipment Co., Ltd., which may lead to increased asset impairment losses[10]